RNL 26 Report: RA-ILD

Rheumatologist discusses recent advances in interstitial lung disease associated with rheumatoid arthritis

Published on Feb. 11, 2026

Got story updates? Submit your updates here. ›

Audrey Gibson, a physician assistant, reports from RheumNow Live 2026 in Dallas, Texas, on a lecture given by Dr. Jeffrey Sparks about recent advances in the understanding and treatment of interstitial lung disease (ILD) associated with rheumatoid arthritis (RA).

Why it matters

Rheumatoid arthritis is a chronic autoimmune disease that can lead to a variety of extra-articular manifestations, including interstitial lung disease, which is a serious complication that can significantly impact patient outcomes. Understanding the latest research and treatment approaches for RA-associated ILD is crucial for rheumatologists and other healthcare providers managing these complex patients.

The details

Dr. Sparks' lecture at RheumNow Live 2026 focused on reviewing the epidemiology, pathogenesis, diagnosis, and treatment of ILD in the context of rheumatoid arthritis. He discussed emerging data on risk factors, screening recommendations, and novel therapeutic options for managing this pulmonary complication of RA.

  • The RheumNow Live 2026 conference took place in Dallas, Texas.

The players

Audrey Gibson

A physician assistant who reported on the lecture at RheumNow Live 2026.

Dr. Jeffrey Sparks

A rheumatologist who gave a lecture on recent advances in interstitial lung disease associated with rheumatoid arthritis at RheumNow Live 2026.

Got photos? Submit your photos here. ›

What they’re saying

“Rheumatoid arthritis is a chronic autoimmune disease that can lead to a variety of extra-articular manifestations, including interstitial lung disease, which is a serious complication that can significantly impact patient outcomes.”

— Audrey Gibson, Physician Assistant (rheumnow.com)

The takeaway

The lecture by Dr. Sparks at RheumNow Live 2026 highlighted the importance of understanding the latest research and treatment approaches for managing interstitial lung disease in patients with rheumatoid arthritis, a serious complication that can significantly impact patient health and outcomes.